as nasdaq pphm nasdaq pphmp industry pharmaceuticals founded 1981 headquarters tustin california united states key people steven w. king president and ceo revenue us 26.781 million 2015 1 operating income us 50.499 million 2015 1 net income us 50.358 million 2015 1 total assets us 97.464 million 2015 1 total equity us 97.646 million 2015 1 number of employees 215 april 30 2015 1 website www.peregrineinc.com peregrine pharmaceuticals inc. is a publicly traded american biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials as potential cancer treatments and diagnostic agents . as of 2016 their lead product candidate was bavituximab . it also has a revenue generating subsidiary avid bioservices which is a contract manufacturing organization that provides services to peregrine and to other companies . contents 1 history 2 products in development 2.1 bavituximab 2.2 124i pgn650 2.3 cotara 3 references history edit peregrine was founded in 1981 . 1 in 2002 peregrine established a wholly owned subsidiary avid bioservices a contract manufacturing organization that provides cgmp development and biomanufacturing services for both peregrine and outside customers . 2 in 2015 avid had revenues of about 27 million about 80 % of which came under contract from halozyme therapeutics . 1 products in development edit bavituximab edit it has been suggested that this section be split out into another article titled bavituximab . discuss march 2016 bavituximab pgn401 is a human mouse chimeric monoclonal antibody against phosphatidylserine which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies 3 4 and when cells are infected with hepatitis c. 5 the process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it the conjugate appears to stimulate an immune response in humans . 4 bavituximab was invented at university of texas southwestern medical center at dallas ; peregrine exclusively licensed intellectual property related to bavituximab from the university including us patent 6 300 308 invented by alan j. schroit and us patents 6 406 693 and 6 312 694 invented in the laboratory philip e. thorpe . 1 6 6 in june 2014 the fda granted peregrine fast track status as a second line drug candidate for non small cell lung cancer . 7 as of january 2016 bavituximab had been in a phase iii clinical trial for non small cell lung cancer a phase ii iii trial for breast cancer a phase ii trial for pancreatic cancer a phase i ii trial for hepatocellular carcinoma and phase i clinical trials in malignant melanoma and rectal cancer ; its development had been discontinued for influenza and prostate cancer . 3 as of 2011 it had been in a phase ii trial for hepatitis c 5 but no results had been reported as of 2016 . 3 124i pgn650 edit example image from preclinical studies 124i pgn650 is a phosphatidylserine targeting f ab 2 fully human monoclonal antibody fragment joined to the pet imaging radio isotope iodine 124 being developed to obtain medical images of cancer . 8 cotara edit cotara 131i chtnt 1 b is a chimeric monoclonal antibody against dna histone h1 complex called tnt 1 conjugated to the radioisotope iodine 131 . 9 10 as of 2016 peregrine was developing it for glioblastoma multiforme ; it has been granted orphan status in europe and the us . 10 references edit a b c d e f g h i 2015 form 10 k peregrine pharmaceuticals . united states securities and exchange commission . staff pharma live . november 11th 2011 global contract manufacturing companies pharmaceutical and biotechnology a b c staff adis insight . bavituximab profile last updated jan 27 2016 a b mahoney k. m. ; rennert p. d. ; freeman g. j. august 2015 . combination cancer immunotherapy and new immunomodulatory targets . nature reviews . drug discovery . 14 8 561 84 . doi 10.1038 nrd4591 . pmid 26228759 . a b ahn j flamm sl . hepatitis c therapy other players in the game . clin liver dis . 2011 aug ; 15 3 641 56 . pmid 21867942 peregrine press release peregrine pharmaceuticals licenses additional intellectual property for its anti phospholipid therapy platform technology . july 6 2004 staff the pharma letter . hune 1 2014 us fda grants peregrine fast track designation for bavituximab in nsclc biocentury 124i pgn650 profile . page accessed february 12 2016 hdeib a sloan a. targeted radioimmunotherapy the role of 131i chtnt 1 b mab cotara for treatment of high grade gliomas . future oncol . 2012 jun ; 8 6 659 69 . pmid 22764763 a b uk medicines information new drugs online cotara . ukmi . retrieved 2 february 2015 . retrieved from https en.wikipedia.org w index.php title peregrine pharmaceuticals & oldid 733985877 categories pharmaceutical companies of the united stateshidden categories use dmy dates from august 2014articles to be split from march 2016all articles to be split navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 11 august 2016 at 11 16 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view